Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The new generation of target-specific oral anticoagulants is being prescribed for increasing numbers of patients at risk of stroke or venous thromboembolism (VTE). These drugs offer valuable benefits due to fast onset anticoagulation, a fixed anticoagulation effect (allowing administration of specified doses), and no requirement for routine monitoring. Edoxaban is a fast-acting oral anticoagulant, approved for use in the prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and in the treatment of acute VTE. Like many of the new oral anticoagulants, it selectively inhibits factor Xa, in a concentration-dependent manner. Multiple Phase II clinical trials have shown edoxaban to be noninferior to vitamin K antagonists in the prevention of stroke and VTE, with a good safety profile. To date, the pivotal studies to endorse edoxaban's clinical use have been ENGAGE AF-TIMI and Hokusai-VTE, both of which have compared its efficacy to standard warfarin treatment. This paper aims at reviewing the use of edoxaban in the management of stroke and thromboembolic disease, highlighting the key study results that have led to its current license.

Original publication

DOI

10.2147/VHRM.S94679

Type

Journal article

Journal

Vasc Health Risk Manag

Publication Date

2016

Volume

12

Pages

329 - 335

Keywords

atrial fibrillation, edoxaban, new oral anticoagulants, randomized controlled trials, stroke management, venous thromboembolism, Administration, Oral, Atrial Fibrillation, Blood Coagulation, Factor Xa Inhibitors, Hemorrhage, Humans, Pyridines, Risk Factors, Stroke, Thiazoles, Treatment Outcome, Venous Thromboembolism